Ciprofibrate D6

Ciprofibrate-d₆ is intended for use as an internal standard for the quantification of ciprofibrate by GC- or LC-MS. Ciprofibrate is an agonist of peroxisome proliferator-activated receptor α (PPARα; EC₅₀ = 0.9 ?M in a transactivation assay).¹ It is selective for PPARα over PPARγ and PPARδ at 300 ?M.² Ciprofibrate (250 ?M) induces cell cycle arrest at the G₂/M and S phases in Fao rat, but not HepG2 human, hepatocellular carcinoma cells.³ It decreases fasting plasma levels of triglycerides and increases fasting plasma glucose levels in the apolipoprotein CIII transgenic mouse model of hypertriglyceridemia when administered at a dose of 10 mg/kg.⁴ Formulations containing ciprofibrate have been used in the treatment of hypertriglyceridemia.

1.Quang, T.H., Ngan, N.T.T., Minh, C.V., et al.Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldiiBioorg. Med. Chem. Lett.22(7)2527-2533(2012) 2.Forman, B.M., Chen, J., and Evans, R.M.Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δProc. Natl. Acad. Sci. USA94(9)4312-4317(1997) 3.Passilly, P., Jannin, B., Hassell, S.J., et al.Human HepG2 and rat Fao hepatic-derived cell lines show different responses to ciprofibrate, a peroxisome proliferator: analysis by flow cytometryExp. Cell. Res.223(2)436-442(1996) 4.Bighetti, E.J.B., Patricio, P.R., Casquero, A.C., et al.Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liverLipids Health Dis.850(2009)